Stock Events

Stock Events

Skye Bioscience 

$5.28
36
+$0.32+6.43% Tuesday 07:09

Statistics

Day High
0.66
Day Low
0.66
52W High
0.8712
52W Low
0.6201
Volume
9
Avg. Volume
-
Mkt Cap
23.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q3 2025
Q1 2026
Q2 2026
Next
-2.16
-1.54
-0.93
-0.31
Expected EPS
-1.141867
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-55.93MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SKYE.BOATS. It's not an investment recommendation.
NVIDIA
8
NVDA
Microsoft
7
MSFT
Apple
6
AAPL
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap214.3M
Corbus Pharmaceuticals works on developing and commercializing novel therapeutics to treat inflammatory and fibrotic diseases, overlapping with some of Skye Bioscience's therapeutic targets.
Aurora Cannabis
ACB
Mkt Cap250.07M
Aurora Cannabis is a major player in the cannabis industry, and while primarily focused on recreational and medicinal cannabis products, its interest in medical research could position it as a competitor in cannabinoid therapeutics.
Tilray Brands
TLRY
Mkt Cap619.11M
Tilray is engaged in pharmaceutical-grade cannabis research, cultivation, processing, and distribution, making it a competitor in the cannabinoid-based pharmaceuticals market.
Canopy Growth
CGC
Mkt Cap437.03M
Canopy Growth Corporation operates in the cannabis and hemp-based consumer product markets but also invests in research and development for cannabinoid-based medicines.
Curaleaf
CURLF
Mkt Cap2.5B
Curaleaf Holdings operates in the cannabis retail and medical cannabis markets, and its involvement in developing cannabis-based medicinal products makes it a competitor in the cannabinoid therapeutics field.

About

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Show more...
CEO
ISIN
US83086J2006

Listings

MU
DE
09R0.MU
F
DE
09R0.F
STU
DE
09R0.STU
XNAS
US
SKYE

0 Comments

Share your thoughts

FAQ

What is Skye Bioscience stock price today?▼
The current price of SKYE.BOATS is $5.28 USD — it has increased by +6.43% in the past 24 hours. Watch Skye Bioscience stock price performance more closely on the chart.
What is Skye Bioscience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Skye Bioscience stocks are traded under the ticker SKYE.BOATS.
What is Skye Bioscience market cap?▼
Today Skye Bioscience has the market capitalization of 23.38M
When is the next Skye Bioscience earnings date?▼
Skye Bioscience is going to release the next earnings report on November 05, 2026.
What were Skye Bioscience earnings last quarter?▼
SKYE.BOATS earnings for the last quarter are -2.16 USD per share, whereas the estimation was -2.04 USD resulting in a -5.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Skye Bioscience revenue for the last year?▼
Skye Bioscience revenue for the last year amounts to 0 USD.
What is Skye Bioscience net income for the last year?▼
SKYE.BOATS net income for the last year is -55.93M USD.
In which sector is Skye Bioscience located?▼
Skye Bioscience operates in the Other sector.
When did Skye Bioscience complete a stock split?▼
The last stock split for Skye Bioscience was on August 24, 2026 with a ratio of 1:8.